India May Ban Popular Antacid Ranitidine After Years Of Deliberation On Cancer Risks, Expert Panel Files Report
Ranitidine reduces the amount of acid in the stomach and relieves acid-related indigestion and heartburn. It is sold under popular brand names like Aciloc, Rantac and Zinetac
After years of deliberation, India is likely to ban the widely used over-the-counter (OTC) antacid Ranitidine due to cancer-causing concerns, News18 has learnt.
The ban has been recommended by an expert panel, and its report has been submitted to the apex body, Drug Technical Advisory Board (DTAB), which advises the Drug Controller General of India on regulatory actions.
According to the latest agenda document for the meeting of the Drug Technical Advisory Board, seen by News18, DTAB is slated to discuss this report recommending the 'suspension of the drug ranitidine for manufacture, sale and distribution in the country".
Among several observations, the report noted that of the 42 Ranitidine samples tested at the Central Drug Laboratory in Kolkata, 21 were found to contain NDMA impurities exceeding 0.32 PPM. This level surpasses the globally acceptable limit for the impurity, which is linked to an increased risk of cancer over a lifetime.
The drug Ranitidine reduces the amount of acid made in the stomach, and it relieves acid-related indigestion and heartburn. It is sold under popular brand names such as Aciloc, Rantac, and Zinetac. However, this category of medicines has been under scrutiny since 2019, when the US Food and Drug Administration alerted about a drug that contains low levels of cancer-causing substances.
The US FDA had suggested that some Ranitidine medicines contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. 'NDMA is classified as a probable human carcinogen—a substance that could cause cancer—based on results from laboratory tests," the FDA had said earlier.
India had been deliberating over the use of this category of drugs since then. Meanwhile, in 2022, the central government dropped the drug from the national list of essential medicines (NLEM) due to cancer-causing concerns.
What does the latest report say?
The agenda document, seen by News18, lists 'Consideration of the proposal to examine the safety related to Ranitidine drug due to the presence of NDMA impurity".
It said that the 'safety issue related to the Ranitidine drug due to the presence of NDMA impurity has been under consideration for quite some time, and CDSCO has taken various measures from time to time".
It recalls that 'Ranitidine was in the National List of Essential Medicines (NLEM), 2015. However, it was deleted and does not appear in NLEM, 2022".
To have a broad-based decision in the matter, an expert committee was constituted in 2024. Now, the subcommittee has submitted its report for further deliberation at the DTAB meeting.
'After detailed deliberation, the committee recommended for suspension of the drug Ranitidine for manufacture, sale and distribution in the country," said the document while attaching the report submitted by the panel.
However, the subcommittee and DTAB can only deliberate on the issue and submit their recommendation on the matter to the apex authority, the Drug Controller General of India (DCGI). The final move kicks in only when DCGI approves DTAB's recommendations.
Report submitted by panel to DTAB
The panel—led by Dr Vineet Ahuja, Department of Gastroenterology at All India Institute of Medical Sciences (AIIMS), New Delhi—noted that 'international regulatory agencies and available literature mention that ranitidine may contain a nitrosamine impurity called NDMA at low levels".
From the presentation delivered by the members of the committee, the panel found that 'NDMA and NDEA belong to the 'cohort of concern', which is a group of highly potent mutagenic carcinogens that have been classified by the WHO's International Agency for Research on Cancer as probably human carcinogens".
'Various studies conducted revealed that the presence of NDMA may result from a slow degradation of the ranitidine molecule through the intermolecular reaction of ranitidine hydrochloride without the involvement of impurities," it said.
The report also noted that 'Ranitidine hydrochloride and its inherent Impurities A, C, D, E, H, and NDMA at different rates in ranitidine".
The subcommittee observed that the internationally acceptable intake limit of NDMA is 96 ng per day or 0.32 ppm of NDMA in the active ingredient. However, 'Total 42 samples of Ranitidine API were tested in CDL, Kolkata, out of which 21 samples were found to have NDMA impurity more than 0.32 PPM (ranged from 0.336 PPM – 5.19 PPM)."
'The acceptable intake (AI) limit for nitrosamines in drugs is generally set to correspond to an increased cancer risk of one additional case in 100,000 subjects over a lifetime of 70 years," the report said.
The subcommittee has reviewed the decisions of different stringent regulatory authorities on the drug Ranitidine, including the US, Japan, Europe, Australia, and Canada, among others. 'The committee concluded that the drug Ranitidine is withdrawn/suspended by regulatory agencies such as USFDA, EMA, TGA and is no longer being distributed in the USA, EU, Australia and Japan," said the report.
The panel also observed that other standard-of-care drugs to treat heartburn by reducing stomach acid and preventing gastric reflux and ulcers are already available in the country.
top videos
View all
'…after evaluating the global regulatory status of the drug ranitidine and observation that global regulatory authorities have discontinued the drug ranitidine due to concerns over NDMA contamination and as the chemical structure of ranitidine predisposes the risk of nitrosamine impurity and as some of the samples tested were within NDMA acceptable level whereas some sample were out of the limit," said the report.
The panel, as a precautionary measure, recommends 'suspension of drug Ranitidine for manufacture, sale and distribution in the country. However, the committee opined that people taking ranitidine should consult their healthcare professional for other treatment options".
tags :
drug medicine
Location :
New Delhi, India, India
First Published:
April 22, 2025, 19:15 IST
News india India May Ban Popular Antacid Ranitidine After Years Of Deliberation On Cancer Risks, Expert Panel Files Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
a day ago
- India Gazette
India has taken a proactive and forward-thinking approach to extreme heat risk management under leadership of PM Modi: Dr P K Mishra
New Delhi [India], June 7 (ANI): Principal Secretary to the Prime Minister, PK Mishra, has emphasised the urgent need to address extreme heat as a global crisis, echoing the call from the UN Secretary-General. Delivering the keynote address during the Special Session on Extreme Heat Risk Governance at Geneva on Friday, he underlined that rising temperatures pose a systemic risk to public health, economic stability, and ecological resilience, according to a PMO statement. India welcomes the UNDRR's initiative to advance the Common Framework for Extreme Heat Risk Governance as a platform for shared learning, guidance, and collaboration. Mishra emphasised that under the leadership of Prime Minister Shri Narendra Modi, India has taken a proactive and forward-thinking approach to extreme heat risk management. He pointed out that India has moved beyond disaster response toward integrated preparedness and mitigation strategies. Since 2016, the National Disaster Management Authority (NDMA) has developed comprehensive national guidelines on heatwave management, revised in 2019, which laid the foundation for decentralised Heat Action Plans (HAPs). He acknowledged the pioneering Ahmedabad Heat Action Plan, which demonstrated how early warnings, inter-agency coordination, and community outreach can save lives. 'Over 250 cities and districts across 23 heat-prone states have operational Heat Action Plans, supported by NDMA's advisory, technical, and institutional mechanisms', stressed the Principal Secretary, underscoring that strengthened surveillance, hospital readiness, and awareness campaigns have significantly reduced heatwave-related mortality. Mishra highlighted that India's approach is whole-of-government and whole-of-society, engaging ministries from health, agriculture, urban development, labour, power, water, education, and infrastructure. He noted that public health institutes, research groups, civil society organisations, and universities are playing a crucial role in supporting local governments in improving heat action plans. 'Extreme heat deeply impacts communities, and India has actively incorporated traditional wisdom and local experiences into its response', stressed Dr Mishra. He noted that schools have become catalysts for behavioural change, educating children about climate resilience. He also emphasised that hospitals and primary health centres must be strengthened to ensure swift and effective emergency responses. Outlining India's transition from a preparedness-only approach to long-term heatwave mitigation, including cool roof technologies, passive cooling centres, urban greening, and the revival of traditional water bodies, Shri Mishra affirmed that India is integrating Urban Heat Island (UHI) assessments into city planning. Mishra announced a major policy shift, stating that National and State Disaster Mitigation Funds (SDMF) can now be used for heatwave mitigation. This allows local governments, private sector entities, NGOs, and individuals to co-finance prevention and mitigation projects, fostering shared responsibility. Mishra acknowledged key challenges that remain and called for a global focus on developing a localized heat-humidity index based on real-time data to enhance early warning systems, advancing affordable and culturally appropriate building technologies and passive cooling innovations, and addressing equity concerns, as extreme heat disproportionately affects women, outdoor workers, the elderly, and children. 'Heatwaves are transboundary and systemic risks, particularly for densely populated urban areas', stressed Dr Mishra, urging the international community to enhance technological collaboration, data sharing, and joint research on heat resilience. He called for the Common Framework to provide accessible knowledge, research, and practical solutions, alongside institutional and financial support mechanisms. As per the statement, Mishra affirmed India's full commitment to sharing its expertise, technical capacities, and institutional strengths with global partners, ensuring a resilient, coordinated, and proactive global response to extreme heat.(ANI)
Business Standard
a day ago
- Business Standard
India Ramps Up Community Preparedness for Disasters: CBDM India 2025 in Bengaluru to Champion Health Resilience and Local Response
PNN Bengaluru (Karnataka) [India], June 7: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises--including the recent cross-border tensions in northern districts--CBDM India 2025 emerges as a timely national response mechanism rooted in community resilience and emergency health preparedness. The International Conference on 'Disaster Resilience: Community-Based Systems to Save Lives and Preserve Health' will be held on June 20-21 at the JN Tata Auditorium, Indian Institute of Science (IISc), Bengaluru, with a Pre-Conference Workshop on June 19 at the Indian Railways Institute of Disaster Management (IRIDM). -Against the backdrop of natural disasters and the recent border conflict, CBDM India on June 20-21 will showcase people-centric disaster management systems to protect lives & preserve health - A Pre-Conference Workshop on June 19 will provide practical training in rapid response, triage, community mobilization, and emergency communications at IRIDM, Bengaluru Organised by JeevaRaksha Trust, in collaboration with Indian Institute of Science, Rajiv Gandhi University of Health Sciences (RGUHS), Government of Karnataka, Indian Medical Association (IMA) Saragur, Swami Vivekananda Youth Movement, IRIDM, and premier national agencies including NDMA, ISRO, and NIMHANS, this global platform reflects India's growing commitment to proactive, inclusive disaster readiness. From flash floods and heatwaves to border hostilities and civil emergencies, the call for empowered, prepared communities has never been louder. The conference will feature keynote insights from Lt Gen Syed Ata Hasnain (Retd), PVSM, Member, National Disaster Management Authority (NDMA), Government of India. His unique civil-military perspective--especially in conflict-prone zones like Kashmir--will add strategic depth to discussions on disaster coordination in high-risk border and rural areas. Dr. (Flt Lt) M.A. Balasubramanya, Managing Trustee of JeevaRaksha and Chairman of the Organising Committee, said, "In disaster situations--whether caused by nature or conflict--every life saved is a victory of preparedness. The recent Indo-Pak flare-ups in border areas are a reminder that India must be ready not just with diplomacy or arms, but also with health, speed, and compassion. We must train our people, strengthen our health systems, and localise our response." CBDM India 2025 will tackle urgent priorities such as local risk mapping, public health intervention strategies, disaster psychology, digital alert systems, and inter-sectoral coordination. Sessions will explore how community-based models can be integrated with national response systems to create a more agile, informed, and resilient India. The conference will also offer hands-on workshops and case studies from India and the Global South, making it a knowledge hub for low-resource but high-impact solutions. "This is not just a technical event. It is a convergence of policy, science, public health, and lived realities. We are gathering voices from the field--doctors, emergency workers, village leaders, and military medics--to build a framework that saves lives when seconds matter. Whether it's a landslide, flash flood, or border shelling, it's the community that responds first," added Dr. Ram K Nair, Technical Director of JeevaRaksha and Organising Secretary, CBDM 2025. The conference expects participation from over 800 delegates, including officials from disaster management authorities, armed forces, healthcare institutions, academia, civil society, and youth networks. Institutions such as Armed Forces Medical Services, IISc, ISRO, Karnataka State Disaster Management Authority, and NIMHANS will lend technical support and vision. Adding a public health lens, Dr. Prakash K H, CEO of JeevaRaksha, said, "The idea that only governments or uniformed forces handle disasters is outdated. It's time to put people at the centre. This conference will show how villages, wards, hospitals, and schools can become strongholds of resilience. A JeevaRaksha-trained teacher or a connected ASHA can make the difference between life and loss in those first critical moments." CBDM India 2025 also opens the floor to innovation, inviting paper and poster submissions showcasing real-world solutions, best practices, and policy recommendations. The Pre-Conference Workshop on June 19 will provide practical training in rapid response, triage, community mobilisation, and emergency communications at IRIDM, Bengaluru. In a time of compounded crises--raging rivers and restless borders--CBDM India 2025 is India's declaration of readiness, rooted not just in policy, but in people. About JeevaRaksha JeevaRaksha Trust (JR), a special-purpose vehicle established by Rajiv Gandhi University of Health Sciences, Karnataka, and Swami Vivekananda Youth Movement, offers skill courses in Emergency Care. These unique, comprehensive university-certified courses equip doctors, nurses, paramedics, and the public with essential skills to enhance the emergency care response system and save lives. JR has three verticals to strengthen its mission, namely, Emergency Skills Education, Research & Development, and Relief & Rehabilitation, with a strong emphasis on inclusive and innovative disaster management solutions.
News18
a day ago
- News18
81,000 Vials, Rs 24 Crore In 3 Months: Weight Loss Drug Mounjaro Sales Triple As Patients Shift To Higher Dose
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March In a sign of rising adoption, sales of Mounjaro—the breakthrough weight loss and type 2 diabetes drug—have nearly tripled in the last two months, data shows. American drugmaker Eli Lilly launched Mounjaro in India on March 20, triggering immediate frenzy, especially among those looking to achieve weight loss and glucose control. Doctors told News18 they were flooded with requests from patients eager to start Mounjaro or learn more about its benefits. With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March. The higher dosage form of five milligram, in particular, more than doubled in value and quantity sales between April and May, indicating a strong trend of patient progression to the next stage of treatment. As per the medical protocol, patients start with lower dosage of 2.5 milligram weekly dose and upgrade to 5 milligram after four weeks. 'This clinical shift is clearly reflected in market numbers. Five mg pack sales jumped from Rs 3.08 crore in April to Rs 7.53 crore in May, while unit sales rose from over 9,300 to over 22,900," Sheetal Sapale, vice-president (commercial), Pharmatrac, told News18. 'Looking at these trends and the acceptance of this therapy—by physicians as well as patients—along with the affordable pricing of Rs 18,000 to Rs 22,000 per month dosage indicates a definite pick up in consumption." The total market for Mounjaro has reached Rs 23.94 crore over the past three months, selling more than 81,000 vials of the drug—signalling growing adoption in diabetes care protocols. According to Dr Anoop Misra, chairman, Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, clinical use of Mounjaro in India closely reflects the trends observed in the data. 'A substantial number of patients are being initiated at 2.5 mg, with a timely escalation to 5 mg in line with recommended protocols. This pattern suggests good tolerability and early clinical efficacy in glycemic control and weight reduction." Misra told News18: 'With growing familiarity and broader access, increased use of higher doses (7.5 mg and above) is likely, especially in patients requiring enhanced metabolic outcomes." The injectable drug is approved by India's apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO). Mounjaro is a once-weekly injection priced at Rs 4,375 for a 5 mg vial and Rs 3,500 for a 2.5 mg vial, making the monthly expenditure around Rs 14,000-Rs 17,500. The drug is claimed to be 80 per cent cheaper than in the United States. Entry-Level Dosage Sales Plateau Mounjaro, the brand name for Tirzepatide, a once-weekly injectable, is a first-in-class medication that combines the effects of two naturally occurring hormones: GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1). Data shows that the 2.5mg dose of Mounjaro—generally prescribed as the starting regimen for type 2 diabetes patients or those looking to shed weight—has shown signs of 'plateauing growth". This trend confirms a gradual shift to higher doses. The sales value for the 2.5 mg injection rose marginally from Rs 4.80 crore in April to Rs 5.08 crore in May, after a steeper increase from Rs 1.42 crore in March. The data shows that the unit sales also reflect this trend, increasing from 5,400 in March to 18,270 in April, but only marginally to 19,350 in May. While the 2.5 mg variant remains essential for entry-level patient initiation, its month-on-month growth may continue to taper off as the patient base matures and advances to the next phase of dosing.
